Polycythemia Vera Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Novartis, Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma, Perseus Proteomics, Protagonist

DelveInsight's "Polycythemia Vera Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Polycythemia Vera, historical and forecasted epidemiology as well as the Polycythemia Vera market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Polycythemia Vera market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Polycythemia Vera Market Forecast
https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Polycythemia Vera Market Report:
• The Polycythemia Vera market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Orphanet reports that polycythemia vera affects 30 persons in Germany for every 100,000 people. When extrapolated to the entire population, this translates to only about 24,000 individuals impacted
• According to the population registered in The Health Improvement Network (THIN), the prevalence in the UK is estimated to be 6.8 per 100,000. About 5-15% of PV patients go on to develop myelofibrosis, and 5-10% develop acute myeloid leukemia
• The United States had the greatest overall number of prevalent Polycythemia Vera cases. In the United States in 2022, there were around 179,000 cases of Polycythemia Vera overall
• Based on estimates, the age group of 0-34 years old accounted for 700 of the lowest number of cases in the United States in 2022, while the age group of >75 years old had the highest number of cases
• Of the EU4 nations, Germany had the highest incidence of Polycythemia Vera cases in 2022-nearly 25,000 cases-while Spain had the lowest incidence
• Potential Polycythemia Vera therapies expected to launch include Rusfertide,Givinostat, KRT-232, Bomedemstat, Sapablursen, Itacitinib, PPMX-T003, and others.
• Key Polycythemia Vera Companies: Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Protagonist Therapeutics, Inc., Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others
• Key Polycythemia Vera Therapies: Rusfertide (PTG-300), Givinostat (ITF2357), Bomedemstat, SLN124, Sapablursen, PPMX-T003, PTG-300, SLN124, Hydroxyurea, Ropeginterferon alfa-2b, PEG-P-INF alpha-2b (P1101), Ruxolitinib, and others
• The Polycythemia Vera epidemiology based on gender analyzed that mostly males are affected in case of Polycythemia Vera
• The Polycythemia Vera market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Polycythemia Vera pipeline products will significantly revolutionize the Polycythemia Vera market dynamics.

Polycythemia Vera Overview
Erythrocytosis, or an increase in red blood cells in the bloodstream, is the hallmark of polycythemia vera (PV); individuals with the condition may also have an excess of white blood cells and platelets. The majority of PV instances are acquired during a person's lifetime and are not inherited.

Get a Free sample for the Polycythemia Vera Market Report
https://www.delveinsight.com/report-store/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Polycythemia Vera Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Polycythemia Vera Epidemiology Segmentation:
The Polycythemia Vera market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Polycythemia Vera
• Prevalent Cases of Polycythemia Vera by severity
• Gender-specific Prevalence of Polycythemia Vera
• Diagnosed Cases of Episodic and Chronic Polycythemia Vera

Download the report to understand which factors are driving Polycythemia Vera epidemiology trends @ Polycythemia Vera Epidemiology Forecast
https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Polycythemia Vera Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Polycythemia Vera market or expected to get launched during the study period. The analysis covers Polycythemia Vera market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Polycythemia Vera Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Polycythemia Vera Therapies and Key Companies
• Rusfertide (PTG-300): Protagonist Therapeutics
• Givinostat (ITF2357): Italfarmaco
• Bomedemstat: Imago BioSciences
• SLN124: Silence Therapeutics
• Sapablursen: Ionis Pharmaceutical
• PPMX-T003: Perseus Proteomics
• PTG-300: Protagonist Therapeutics, Inc.
• SLN124: Silence Therapeutics plc
• Hydroxyurea: Novartis
• Ropeginterferon alfa-2b: PharmaEssentia
• PEG-P-INF alpha-2b (P1101): AOP Orphan Pharmaceuticals AG
• Ruxolitinib: Incyte Corporation

Discover more about therapies set to grab major Polycythemia Vera market share @ Polycythemia Vera Treatment Market
https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Polycythemia Vera Market Strengths
• The recent approval of BESREMi in the US and its expected approval in Japan, in both the first and second line of treatment, provides the interferon with an immense opportunity to garner abig market size in PV.
• Based on increasing sales of JAKAFI/JAKAVI, the drug will be a blockbuster therapy in 2L PV patients.
• Emerging drugs with a novel mechanism of action, like givinostat (HDAC inhibitor), rusfertide (Iron modulator), and others, hold the

Polycythemia Vera Market Opportunities
• Only one drug is approved in first-line; approval in first-line will provide a significant opportunity to capture market share.
• An increase in strategic alliances, such as geographical alliances, and granting the designation such as BTD and FTD by the FDA are some of the factors that will drive the market growth.
• Opportunity for drugs with novel and disease-modifying mechanisms and low side effect.

Scope of the Polycythemia Vera Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Polycythemia Vera Companies: Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Protagonist Therapeutics, Inc., Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others
• Key Polycythemia Vera Therapies: Rusfertide (PTG-300), Givinostat (ITF2357), Bomedemstat, SLN124, Sapablursen, PPMX-T003, PTG-300, SLN124, Hydroxyurea, Ropeginterferon alfa-2b, PEG-P-INF alpha-2b (P1101), Ruxolitinib, and others
• Polycythemia Vera Therapeutic Assessment: Polycythemia Vera current marketed and Polycythemia Vera emerging therapies
• Polycythemia Vera Market Dynamics: Polycythemia Vera market drivers and Polycythemia Vera market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Polycythemia Vera Unmet Needs, KOL's views, Analyst's views, Polycythemia Vera Market Access and Reimbursement

To know more about Polycythemia Vera companies working in the treatment market, visit @ Polycythemia Vera Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/polycythemia-vera-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Polycythemia Vera Market Report Introduction
2. Executive Summary for Polycythemia Vera
3. SWOT analysis of Polycythemia Vera
4. Polycythemia Vera Patient Share (%) Overview at a Glance
5. Polycythemia Vera Market Overview at a Glance
6. Polycythemia Vera Disease Background and Overview
7. Polycythemia Vera Epidemiology and Patient Population
8. Country-Specific Patient Population of Polycythemia Vera
9. Polycythemia Vera Current Treatment and Medical Practices
10. Polycythemia Vera Unmet Needs
11. Polycythemia Vera Emerging Therapies
12. Polycythemia Vera Market Outlook
13. Country-Wise Polycythemia Vera Market Analysis (2019-2032)
14. Polycythemia Vera Market Access and Reimbursement of Therapies
15. Polycythemia Vera Market Drivers
16. Polycythemia Vera Market Barriers
17. Polycythemia Vera Appendix
18. Polycythemia Vera Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Polycythemia Vera Pipeline https://www.delveinsight.com/report-store/polycythemia-vera-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Polycythemia Vera Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Polycythemia Vera market. A detailed picture of the Polycythemia Vera pipeline landscape is provided, which includes the disease overview and Polycythemia Vera treatment guidelines.
Polycythemia Vera Epidemiology https://www.delveinsight.com/report-store/polycythemia-vera-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Polycythemia Vera Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Polycythemia Vera epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Chemotherapy Drugs Market https://www.delveinsight.com/report-store/chemotherapy-drugs-market
Chemotherapy Drugs Market By Drug Class (Alkylating Agents, Mitotic Inhibitors, Antimetabolites, Topoisomerase Inhibitors, And Others), By Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, And Others), By Route Of Administration (Oral And Parenteral), by geography is estimated to register growth at a remarkable CAGR forecast during 2023-2028 owing to increasing prevalence of different cancer types and increasing pharmaceutical trials for chemotherapy drugs.

Connected Drug Delivery Devices Market
https://www.delveinsight.com/report-store/connected-drug-delivery-devices-market
Connected Drug Delivery Devices Market By Product (Connected Sensors [Connected Inhaler Sensors And Connectable Injection Sensors] And Integrated Connected Devices [Connected Inhaler Devices And Connected Injection Devices], By Technology (Bluetooth, Near-Field Communication (NFC), And Others), By End-User (Healthcare Providers And Homecare), And by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of chronic diseases such as diabetes and improving healthcare it infrastructure across the globe.

Gynecological Devices Market https://www.delveinsight.com/report-store/gynecological-devices-market
Gynecological Devices Market By Product (Gynecological Endoscopy Devices [Hysteroscope, Resectoscope, And Others), Endometrial Ablation Devices [Balloon Ablation Devices, Radiofrequency Ablation Devices, And Others], Contraceptive Devices [Temporary Birth Control And Permanent Birth Control], Diagnostic Imaging Systems, Fluid Management Systems, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Diagnostic Centers, And Others), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of various gynecological ailments and increasing figure of surgical procedures across the globe.

Baby Wipes Market
https://www.delveinsight.com/report-store/baby-wipes-market
Baby Wipes Market By (Wet Wipes And Dry Wipes), By Distribution Channels (Supermarkets And Hypermarkets, E-Commerce, And Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2023-2028 owing to increased adoption of baby wipes for maintaining infant sanitation and increasing product development activities.

Probiotics Market
https://www.delveinsight.com/report-store/probiotics-market
Probiotics Market By Ingredient Type (Bacteria And Yeast), By Product Type (Functional Food And Beverages, Dietary Supplements, And Animal Feed), By Application (Human Nutrition And Animal Nutrition), By Distribution Channels (Supermarkets And Hypermarkets, Convenience Stores, And Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2022-2027 owing to rising demand for probiotics as a preventive healthcare and increasing product development activities.

Artificial Tears Market
https://www.delveinsight.com/report-store/artificial-tears-market
Artificial Tears Market By Product (Cellulose-Derived Tears, Glycerin-Derived Tears, Polyethylene Glycol And Propylene Glycol-Based Tears, And Others), By Delivery Method (Eye Drops And Eye Ointments), By Application (Dry Eye Disease, Allergies And Infections, And Others), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence dry eyes syndrome and increasing availability of over the counter (otc) artificial tears.

Non-invasive Prenatal Testing Market https://www.delveinsight.com/report-store/non-invasive-prenatal-testing-market
Non-Invasive Prenatal Testing Market By Product Type (Instruments And Kits And Reagents), By Indication (Down Syndrome, Edwards Syndrome, Patau Syndrome, Turner Syndrome, And Others), By End-User (Hospitals, Diagnostic Labs, And Others), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of chromosomal disorders and the increasing demand for early and non-invasive fetal diagnosis across the globe.

Orthopedic Implants Market https://www.delveinsight.com/report-store/orthopedic-implants-market
Orthopedic Implants Market By Product Type (Hip Implants, Knee Implants, Spinal Implants, Foot And Ankle Implants, And Others), By End-User (Hospitals, Orthopedic Clinics, And Others ), by geography is estimated to register growth at a remarkable CAGR forecast during 2023-2028 owing to increasing prevalence of orthopedic diseases and rising demand for personalized orthopedic implants.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.